Survival outcomes of advanced and recurrent cervical cancer patients treated with chemotherapy: Experience of northern tertiary care hospital in Thailand

Chemotherapy is the primary treatment for advanced and recurrent cervical cancer. To evaluate the survival outcomes of chemotherapy and the prognostic factors in this setting, we conducted a retrospective study by reviewing the medical records of advanced and recurrent cervical cancer patients treat...

Full description

Saved in:
Bibliographic Details
Main Authors: Boupaijit K., Suprasert P.
Format: Journal
Published: 2017
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84965054297&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/41947
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-41947
record_format dspace
spelling th-cmuir.6653943832-419472017-09-28T04:24:19Z Survival outcomes of advanced and recurrent cervical cancer patients treated with chemotherapy: Experience of northern tertiary care hospital in Thailand Boupaijit K. Suprasert P. Chemotherapy is the primary treatment for advanced and recurrent cervical cancer. To evaluate the survival outcomes of chemotherapy and the prognostic factors in this setting, we conducted a retrospective study by reviewing the medical records of advanced and recurrent cervical cancer patients treated with systemic chemotherapy at our institute between January, 2008 and December, 2014. One hundred and seventy-three patients met the criteria with a mean age of 50.9 years. 4.1% of them were HIV positive. The most common initial stage was stage IVB (30.1%) and the most common histology was squamous cell carcinoma (68.6%). Ninety-two (53.2%) patients were previously treated with concurrent chemoradiation with 53% developing combined sites of recurrence. The median recurrence free interval was 16.7 months. Cisplatin + 5 fluorouracil (5FU) (53.2%) was the most frequent first line chemotherapy followed by carboplatin + paclitaxel (20.2%) with an objective response of 39.3%. Seventy-two patients received subsequent chemotherapy. The median overall survival of all studied patients was 13.2 months. Only a recurrence free interval of less than 12 months was an independent prognostic factor for survival outcome. In conclusion, chemotherapy treatment for advanced and recurrent cervical cancer patients showed modest efficacy with a shorter recurrence free survival less than 12 months as a significant poor prognosis factor. 2017-09-28T04:24:19Z 2017-09-28T04:24:19Z 2016-04-19 Journal 15137368 2-s2.0-84965054297 10.7314/APJCP.2016.17.3.1123 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84965054297&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/41947
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
description Chemotherapy is the primary treatment for advanced and recurrent cervical cancer. To evaluate the survival outcomes of chemotherapy and the prognostic factors in this setting, we conducted a retrospective study by reviewing the medical records of advanced and recurrent cervical cancer patients treated with systemic chemotherapy at our institute between January, 2008 and December, 2014. One hundred and seventy-three patients met the criteria with a mean age of 50.9 years. 4.1% of them were HIV positive. The most common initial stage was stage IVB (30.1%) and the most common histology was squamous cell carcinoma (68.6%). Ninety-two (53.2%) patients were previously treated with concurrent chemoradiation with 53% developing combined sites of recurrence. The median recurrence free interval was 16.7 months. Cisplatin + 5 fluorouracil (5FU) (53.2%) was the most frequent first line chemotherapy followed by carboplatin + paclitaxel (20.2%) with an objective response of 39.3%. Seventy-two patients received subsequent chemotherapy. The median overall survival of all studied patients was 13.2 months. Only a recurrence free interval of less than 12 months was an independent prognostic factor for survival outcome. In conclusion, chemotherapy treatment for advanced and recurrent cervical cancer patients showed modest efficacy with a shorter recurrence free survival less than 12 months as a significant poor prognosis factor.
format Journal
author Boupaijit K.
Suprasert P.
spellingShingle Boupaijit K.
Suprasert P.
Survival outcomes of advanced and recurrent cervical cancer patients treated with chemotherapy: Experience of northern tertiary care hospital in Thailand
author_facet Boupaijit K.
Suprasert P.
author_sort Boupaijit K.
title Survival outcomes of advanced and recurrent cervical cancer patients treated with chemotherapy: Experience of northern tertiary care hospital in Thailand
title_short Survival outcomes of advanced and recurrent cervical cancer patients treated with chemotherapy: Experience of northern tertiary care hospital in Thailand
title_full Survival outcomes of advanced and recurrent cervical cancer patients treated with chemotherapy: Experience of northern tertiary care hospital in Thailand
title_fullStr Survival outcomes of advanced and recurrent cervical cancer patients treated with chemotherapy: Experience of northern tertiary care hospital in Thailand
title_full_unstemmed Survival outcomes of advanced and recurrent cervical cancer patients treated with chemotherapy: Experience of northern tertiary care hospital in Thailand
title_sort survival outcomes of advanced and recurrent cervical cancer patients treated with chemotherapy: experience of northern tertiary care hospital in thailand
publishDate 2017
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84965054297&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/41947
_version_ 1681422096773677056